Positron emission tomography (PET) has become widely used for cardiac disease and several cancers. New sensitive antigen-specific tracers are further extending PET usefulness in other settings, including prostate cancer and Alzheimer’s disease (AD).
Pharma’s use of artificial intelligence and machine learning is growing quickly. How and when should these tools be incorporated? We explore applications in target identification, drug discovery and optimization, clinical trials, manufacturing & commercialization.
This year will see the formation of a new EU health program to strengthen the framework for ongoing coordination between states on measures aimed at disease protection, prevention, preparedness & response.
In our second post exploring trends we expect in the biotech and pharmaceutical development world in 2021, we take a look at digital health, the continuing impact of COVID-19, and growth in pharma investment.